Analysts expect that OraSure Technologies, Inc. (NASDAQ:OSUR) will announce sales of $47.04 million for the current quarter, Zacks reports. Two analysts have provided estimates for OraSure Technologies’ earnings, with estimates ranging from $46.97 million to $47.10 million. OraSure Technologies reported sales of $50.25 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 6.4%. The company is scheduled to report its next earnings report on Wednesday, February 5th.

According to Zacks, analysts expect that OraSure Technologies will report full-year sales of $151.95 million for the current fiscal year, with estimates ranging from $151.90 million to $152.00 million. For the next year, analysts anticipate that the firm will post sales of $170.81 million, with estimates ranging from $164.00 million to $177.61 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, November 6th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.18. The business had revenue of $35.99 million for the quarter, compared to analysts’ expectations of $38.62 million. OraSure Technologies had a return on equity of 5.93% and a net margin of 15.80%. The business’s revenue for the quarter was down 21.6% on a year-over-year basis. During the same period last year, the firm posted $0.13 earnings per share.

Several brokerages have issued reports on OSUR. BidaskClub raised OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Saturday. ValuEngine raised OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Canaccord Genuity reissued a “hold” rating and issued a $8.00 target price on shares of OraSure Technologies in a research report on Monday, November 11th. Finally, Zacks Investment Research cut OraSure Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, November 27th.

Several hedge funds have recently bought and sold shares of OSUR. Acadian Asset Management LLC purchased a new position in shares of OraSure Technologies during the 2nd quarter valued at about $25,000. BSW Wealth Partners purchased a new position in shares of OraSure Technologies during the 2nd quarter valued at about $29,000. Panagora Asset Management Inc. lifted its position in shares of OraSure Technologies by 34.3% during the 2nd quarter. Panagora Asset Management Inc. now owns 9,851 shares of the medical instruments supplier’s stock valued at $91,000 after buying an additional 2,514 shares in the last quarter. Quantamental Technologies LLC lifted its position in shares of OraSure Technologies by 107.0% during the 2nd quarter. Quantamental Technologies LLC now owns 10,311 shares of the medical instruments supplier’s stock valued at $96,000 after buying an additional 5,330 shares in the last quarter. Finally, Pacer Advisors Inc. purchased a new position in shares of OraSure Technologies during the 2nd quarter valued at about $104,000. 95.66% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:OSUR opened at $8.01 on Tuesday. The stock has a market capitalization of $489.52 million, a price-to-earnings ratio of 16.02, a PEG ratio of 4.63 and a beta of 1.20. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.85 and a current ratio of 7.72. The stock’s 50-day simple moving average is $8.25 and its two-hundred day simple moving average is $8.08. OraSure Technologies has a 52-week low of $6.35 and a 52-week high of $13.25.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.

Featured Story: Yield Curve

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.